
Conference Coverage
about 1 hour ago
Real-World Data Support Cemiplimab Efficacy in Advanced NSCLCLatest Content

Atopic Dermatitis Escalation Stalls on Payer Rules, Thin Tracking

Real-World Data Support Cemiplimab Efficacy in Advanced NSCLC

FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC

Emerging Threats to Cell and Gene Therapy Access

FDA Adds Head-to-Head MAPLE-HCM Data to Aficamten Label in oHCM

Shorts










Center on Health Equity & Access
All News

Panelists concurred that precision medicine can serve to exacerbate care inequality if not everyone can access these therapeutics.

IL-23 inhibitors linked to lower psoriatic arthritis risk than JAK inhibitors, and IL-17 inhibitors showed higher risk.

Once weekly tirzepatide significantly reduces body mass index in adolescents with obesity compared with placebo.

Rural patients with HFrEF had lower mortality when treated at urban hospitals but higher early mortality than urban patients at those hospitals.

Report urges payment reform, food policy changes, and wider treatment access, warning that drugs alone can't fix obesity's root causes.

FDA approves dexmedetomidine sublingual film for at-home use in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

Once weekly ribupatide, a dual GIP/GLP-1 receptor agonist, led to significantly greater weight loss than placebo at 48 weeks, according to a study.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

A TriNetX retrospective cohort found adults with alopecia areata—especially women—face a nearly doubled glaucoma risk, with implications for ophthalmology and comorbidities.



























